Teva Pharmaceutical Industries Limited (TEVA)

NYSE (ADR) / TASE · Tel Aviv, Israel · Founded 1901 · CEO Richard Francis

Valuation summary

$19.01 fair value versus $38.54 in the market, a difference of -50.7%. Rated Sell.

Fair value per share$19.01
Current share price$38.54
Upside / downside-50.7%
Bear case$8.97
Bull case$33.36
Discount rate (WACC)9.4%
Terminal growth2.00%
Market capitalisation$45B
EV / Sales3.4x

About Teva Pharmaceutical Industries Limited

Founded in Jerusalem in 1901 as a drug wholesaler, Teva grew into the world's largest maker of generic medicines. A debt-funded acquisition in 2016, falling US generic prices and opioid lawsuits then nearly broke it. Richard Francis became chief executive in 2023 with a plan to shift towards branded medicines: Austedo for movement disorders, Ajovy for migraine and Uzedy for schizophrenia now provide most of the growth, alongside biosimilars.

Investment case

  • Branded products are growing quickly and carry much higher margins than generics.
  • Debt has fallen steadily and credit ratings are improving.
  • A pipeline of biosimilars and new branded drugs.

Key risks

  • Austedo is subject to US government price negotiation.
  • Generics remain a low-margin, competitive business.
  • Debt is still large relative to equity.

Revenue by segment

Generic medicines52%
Innovative medicines30%
Ingredients and other18%

Five-year forecast

RevenueFree cash flow
Year 1$17.4B$2.3B
Year 2$17.9B$2.4B
Year 3$18.4B$2.5B
Year 4$18.9B$2.6B
Year 5$19.4B$2.8B

What the street says

A recovery story that has largely played out; now judged on its branded pipeline.

Comparable companies: BIIB · IQV · GEHC · BDX · TAK · BSX · ELV · GSK

Open the interactive model, price chart and sensitivity grid →